MADISON MALOOF: Open Payments
NPI 1104493220 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,651 in 88 payments from 16 companies in 2025. Trend: 2023 $3,109 · 2024 $2,662 · 2025 $1,651
Food & beverage: $1,651
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $431 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $299 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $210 |
| Janssen Biotech, Inc. | 10 | $178 |
| PFIZER INC. | 5 | $95 |
| Ardelyx, Inc. | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| Lilly USA, LLC | 3 | $56 |
| QOL Medical, LLC | 3 | $54 |
| GENZYME CORPORATION | 1 | $46 |
Products named: RINVOQ, ENTYVIO, XIFAXAN, TREMFYA, DUPIXENT, IBSRELA, XELJANZ, OMVOH.
Industry payments across IN — which companies pay providers there.
